Cardica Launches New C-Port(R) xA X-CHANGE(TM) System in the United States

- Product to be Featured at The Society of Thoracic Surgeons Annual Meeting -

REDWOOD CITY, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Cardica, Inc.
(Nasdaq: CRDC) today announced the launch of its new C-Port(R) xA X-CHANGE(TM)
Distal Anastomosis System, now commercially available in the United States.
The C-Port xA X-CHANGE system, a cartridge-based, reloadable C-Port system,
allows surgeons to attach multiple blood vessel grafts using the same handle
during a coronary artery bypass graft (CABG) procedure, which may reduce
costs. Cardica plans to feature the product at The Society of Thoracic
Surgeons 44th Annual Meeting, the largest gathering of cardiothoracic surgeons
in North America, being held January 28-30, in Fort Lauderdale, FL.
"We are pleased to offer the cartridge-based C-Port xA X-CHANGE system in
response to feedback from surgeons desiring a solution to address all of their
bypass needs with a single handle, which is less expensive than using a new
C-Port system for each anastomosis," said Bernard A. Hausen, M.D., Ph.D.,
president and chief executive officer of Cardica, Inc. "With the introduction
of this product, we will continue to provide surgeons with the same
mechanically-governed, reproducible anastomoses while enhancing the
functionality and providing the ability to perform multiple anastomoses with
one device."
The C-Port xA X-CHANGE system accommodates cartridges pre-loaded with
staples, allowing a surgeon to complete multiple anastomoses using the same
CO2-powered handle. Each device in the C-Port system product line is designed
to enable automated, reliable and reproducible connections of blood vessels
during cardiac bypass surgery. Unlike most hand-sewn anastomoses, Cardica's
C-Port systems create compliant anastomoses that can expand and contract with
blood flow. In addition, the C-Port anastomosis systems, whether used during
on- or off- pump surgery, offer surgeons unique access to a wide range of
coronary arteries, particularly small coronary arteries, which, in the past,
have been difficult or impossible to connect effectively.
The product received 510(k) clearance from the U.S. Food and Drug
Administration in December 2007.
About Cardica
Cardica is a leading provider of automated anastomosis systems for
coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures
with easy-to-use automated systems, Cardica's products provide cardiovascular
surgeons with rapid, reliable and consistently reproducible anastomoses, or
connections of blood vessels, often considered the most critical aspect of the
CABG procedure. Cardica's C-Port(R) Distal Anastomosis Systems are marketed
in Europe and the United States. The PAS-Port(R) Proximal Anastomosis System
is marketed in Europe and Japan and is being evaluated in a pivotal trial in
the United States and Europe. Cardica also is developing additional devices
with Cook Incorporated to facilitate vascular closure and other surgical
procedures.
Forward-Looking Statements
This press release contains "forward-looking" statements, including
statements relating to the expected cost savings created by the C-Port xA
X-CHANGE system. Any statements contained in this press release that are not
historical facts may be deemed to be forward-looking statements. The words
"will", "may," and similar expressions are intended to identify
forward-looking statements. There are a number of important factors that
could cause Cardica's results to differ materially from those indicated by
these forward-looking statements, including risks associated with market
acceptance of Cardica's C-Port and C-Port xA X-CHANGE systems and long-term
patency of CABG grafts completed with Cardica's C-Port and C-Port xA X-CHANGE
systems, as well as other risks detailed from time to time in Cardica's SEC
reports, including its Quarterly Report on Form 10-Q for the fiscal quarter
ended September 30, 2007. Cardica does not undertake any obligation to update
forward-looking statements. You are encouraged to read the Company's reports
filed with the U.S. Securities and Exchange Commission, available at
http://www.sec.gov.
SOURCE Cardica, Inc.

Bob Newell, Vice President, Finance and Operations, Chief Financial Officer,
of Cardica, Inc., +1-650-331-7133, investors@cardica.com; or Daryl Messinger
of WeissComm Partners, Inc., +1-415-999-2361, dmessinger@wcpglobal.com